A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition

NCT00287066 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2008-02-21

No results posted yet for this study

Summary

To assess the impact of inhalation of insulin on glucose disposition in patients with type 1 diabetes

Conditions

Interventions

DRUG

Inhaled Human Insulin

DRUG

Regular Human Insulin

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-02-28
Completion
2007-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00287066 on ClinicalTrials.gov